What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Immune system
Internal medicine, Prostate cancer, Immunology, Oncology and Cancer are his primary areas of study.
His Internal medicine study typically links adjacent topics like Surgery.
The various areas that James L. Gulley examines in his Prostate cancer study include Docetaxel and Urology.
His studies deal with areas such as Malignancy, Combined Modality Therapy, Metastasis, Disease and Combination therapy as well as Oncology.
In the subject of general Cancer, his work in Ipilimumab, Sipuleucel-T and Tumor antigen is often linked to Context, thereby combining diverse domains of study.
His Prostate-specific antigen research incorporates themes from Hormonal therapy and Radiation therapy.
His most cited work include:
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer (808 citations)
- Androgen Deprivation Therapy for Prostate Cancer (791 citations)
- Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. (341 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Oncology, Prostate cancer, Cancer and Immunology.
His research ties Surgery and Internal medicine together.
His Oncology research is multidisciplinary, incorporating elements of Enzalutamide, Disease, Chemotherapy and Combination therapy.
He has researched Prostate cancer in several fields, including Prostate and Ipilimumab.
The study incorporates disciplines such as Tumor microenvironment and Radiation therapy in addition to Immunotherapy.
His research integrates issues of Cancer research and Peripheral blood mononuclear cell in his study of Immune system.
He most often published in these fields:
- Internal medicine (57.80%)
- Oncology (49.29%)
- Prostate cancer (46.10%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (57.80%)
- Oncology (49.29%)
- Prostate cancer (46.10%)
In recent papers he was focusing on the following fields of study:
His main research concerns Internal medicine, Oncology, Prostate cancer, Cancer research and Immunotherapy.
His Internal medicine study frequently intersects with other fields, such as Gastroenterology.
His work carried out in the field of Oncology brings together such families of science as Immune checkpoint, Circulating tumor cell and Phases of clinical research.
Prostate cancer and Prostate are commonly linked in his work.
He interconnects Transforming growth factor, PD-L1, Monoclonal antibody and T cell in the investigation of issues within Cancer research.
His Immunotherapy research includes themes of Disease and Antigen.
Between 2017 and 2021, his most popular works were:
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial (260 citations)
- Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors (137 citations)
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. (100 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Immune system
James L. Gulley mostly deals with Internal medicine, Immunotherapy, Oncology, Adverse effect and Clinical trial.
His work deals with themes such as Gastroenterology and Antibody, which intersect with Internal medicine.
His Immunotherapy study integrates concerns from other disciplines, such as Cancer research, Tolerability and Combination therapy.
His Oncology research includes elements of Immune checkpoint, Enzalutamide, Prostate cancer and Disease.
His Prostate cancer research incorporates elements of Concordance and Prostate.
His Clinical trial research integrates issues from Neoadjuvant therapy, Metastatic Urothelial Carcinoma, Blockade and Chemotherapy regimen.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
